Atara Historical Financial Ratios
| ATRA Stock | USD 10.35 0.16 1.52% |
Atara Biotherapeutics is presently reporting on over 108 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Dividend Yield of 0.0, Days Sales Outstanding of 1.5 K or Invested Capital of 0.0 will help investors to properly organize and evaluate Atara Biotherapeutics financial condition quickly.
Atara |
About Atara Financial Ratios Analysis
Atara BiotherapeuticsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Atara Biotherapeutics investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Atara financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Atara Biotherapeutics history.
Atara Biotherapeutics Financial Ratios Chart
Add Fundamental
Dividend Yield
Dividend Yield is Atara Biotherapeutics dividend as a percentage of Atara Biotherapeutics stock price. Atara Biotherapeutics dividend yield is a measure of Atara Biotherapeutics stock productivity, which can be interpreted as interest rate earned on an Atara Biotherapeutics investment. A financial ratio that shows how much a company pays out in dividends each year relative to its stock price, calculated as annual dividends per share divided by price per share.Book Value Per Share
The ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of a company according to its financial statements.Most ratios from Atara Biotherapeutics' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Atara Biotherapeutics current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Atara Biotherapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Atara Stock refer to our How to Trade Atara Stock guide.At present, Atara Biotherapeutics' ROIC is projected to slightly decrease based on the last few years of reporting. The current year's Payables Turnover is expected to grow to 2.53, whereas PTB Ratio is forecasted to decline to (0.57).
| 2022 | 2023 | 2024 (projected) | Payables Turnover | 2.12 | 2.41 | 2.53 | Days Of Inventory On Hand | 39.74 | 398.68 | 418.62 |
Atara Biotherapeutics fundamentals Correlations
Click cells to compare fundamentals
Atara Biotherapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Atara Biotherapeutics fundamentals Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Ptb Ratio | 2.91 | 3.14 | 5.28 | 2.64 | (0.55) | (0.57) | |
| Book Value Per Share | 141.68 | 156.25 | 74.63 | 31.04 | (23.42) | (22.25) | |
| Operating Cash Flow Per Share | (114.81) | (61.09) | (58.86) | (66.29) | (45.55) | (47.83) | |
| Capex To Depreciation | 0.81 | 0.54 | 1.13 | 0.74 | 0.25 | 0.24 | |
| Pb Ratio | 2.91 | 3.14 | 5.28 | 2.64 | (0.55) | (0.57) | |
| Free Cash Flow Per Share | (117.6) | (62.61) | (61.68) | (67.32) | (45.84) | (48.13) | |
| Roic | (1.02) | (0.67) | (1.22) | (2.22) | 2.78 | 2.92 | |
| Net Income Per Share | (1.4K) | (1.0K) | (907.82) | (559.62) | (65.18) | (68.44) | |
| Cash Per Share | 126.25 | 169.2 | 99.04 | 59.52 | 12.21 | 11.6 | |
| Pocfratio | (3.59) | (8.03) | (6.69) | (1.24) | (0.28) | (0.3) | |
| Capex To Operating Cash Flow | (0.0243) | (0.025) | (0.048) | (0.0155) | (0.006338) | (0.006654) | |
| Pfcf Ratio | (3.5) | (7.84) | (6.39) | (1.22) | (0.28) | (0.29) | |
| Days Payables Outstanding | 358.61 | 263.31 | 557.06 | 172.15 | 151.32 | 143.76 | |
| Income Quality | 0.73 | 0.78 | 0.81 | 1.18 | 0.7 | 0.55 | |
| Roe | (10.01) | (6.63) | (12.16) | (18.03) | 2.78 | 2.92 | |
| Ev To Operating Cash Flow | (3.33) | (7.0) | (6.33) | (1.16) | (0.45) | (0.47) | |
| Pe Ratio | (0.29) | (0.47) | (0.43) | (0.15) | (0.2) | (0.21) | |
| Return On Tangible Assets | (8.48) | (5.21) | (7.27) | (6.07) | (1.67) | (1.75) | |
| Ev To Free Cash Flow | (3.25) | (6.83) | (6.04) | (1.14) | (0.44) | (0.47) | |
| Earnings Yield | (3.44) | (2.11) | (2.3) | (6.82) | (5.08) | (5.34) | |
| Net Debt To E B I T D A | 0.21 | 0.63 | 0.24 | 0.0994 | (0.12) | (0.11) | |
| Current Ratio | 7.43 | 6.31 | 3.64 | 3.74 | 0.72 | 0.68 | |
| Tangible Book Value Per Share | 141.68 | 156.25 | 74.63 | 31.04 | (23.42) | (22.25) | |
| Graham Number | 2.1K | 1.9K | 1.2K | 625.19 | 185.34 | 176.07 | |
| Shareholders Equity Per Share | 141.68 | 156.25 | 74.63 | 31.04 | (23.42) | (22.25) | |
| Capex Per Share | 2.79 | 1.53 | 2.82 | 1.03 | 0.29 | 0.27 | |
| Graham Net Net | 100.84 | 127.01 | 48.92 | 5.88 | (43.1) | (40.94) | |
| Enterprise Value Over E B I T D A | (2.77) | (4.26) | (4.22) | (1.47) | (0.32) | (0.34) | |
| Price Earnings Ratio | (0.29) | (0.47) | (0.43) | (0.15) | (0.2) | (0.21) | |
| Price Book Value Ratio | 2.91 | 3.14 | 5.28 | 2.64 | (0.55) | (0.57) | |
| Price Earnings To Growth Ratio | (0.0377) | 0.0176 | 0.035 | 0.00382 | (0.0119) | (0.0113) | |
| Days Of Payables Outstanding | 358.61 | 263.31 | 557.06 | 172.15 | 151.32 | 143.76 | |
| Price To Operating Cash Flows Ratio | (3.59) | (8.03) | (6.69) | (1.24) | (0.28) | (0.3) | |
| Price To Free Cash Flows Ratio | (3.5) | (7.84) | (6.39) | (1.22) | (0.28) | (0.29) | |
| Effective Tax Rate | (4.1E-5) | (4.9E-5) | (1.35E-4) | (5.3E-5) | (5.4E-5) | (5.7E-5) | |
| Company Equity Multiplier | 1.18 | 1.27 | 1.67 | 2.97 | (1.67) | (1.58) | |
| Return On Capital Employed | (0.67) | (0.97) | (0.61) | (0.94) | (11.86) | (11.26) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Atara Biotherapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Atara Biotherapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Atara Biotherapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Atara Biotherapeutics Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Atara Biotherapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Atara Stock refer to our How to Trade Atara Stock guide.You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Atara Biotherapeutics. If investors know Atara will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Atara Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (25.32) | Revenue Per Share 12.263 | Quarterly Revenue Growth 28.927 | Return On Assets (0.57) | Return On Equity (20.15) |
The market value of Atara Biotherapeutics is measured differently than its book value, which is the value of Atara that is recorded on the company's balance sheet. Investors also form their own opinion of Atara Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Atara Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Atara Biotherapeutics' market value can be influenced by many factors that don't directly affect Atara Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Atara Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Atara Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Atara Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.